Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Significant Expenses Provided to the CODM on a Regular Basis

The following table sets forth the significant expenses provided to the CODM on a regular basis (in thousands):

	Three Months Ended March 31,
	2026		2025
Compensation	$	11,443	$	6,991
Stock-based compensation (1)	12,806		8,859
Research and development, excluding compensation and stock-based compensation (2) (3)	46,893		33,551
Other segment items (4) (5)	(2,137)		(4,628)
Segment net loss	$	69,005	$	44,773

(1) Includes $0.3 million in related party expenses for the three months ended March 31, 2026 and 2025, respectively.

(2) Includes non-clinical study, clinical trial, and manufacturing expenses.

(3) Includes $3.1 million and $2.5 million in related party expenses for the three months ended March 31, 2026 and 2025, respectively.

(4) Includes general and administrative expenses such as audit, legal, and other professional fees, interest income, and other expense, net. Additionally, includes a $30.0 million gain recognized in connection with the sale of pegzilarginase to Immedica for the three months ended March 31, 2026.

(5) Includes $30.3 million increase and a $2.4 million decrease in fair value of CVR liability for the three months ended March 31, 2026 and 2025, respectively.